Treatment of Tinea Corporis

First-Line Treatment Options

• Oral antifungal therapy is indicated when the infection is resistant to topical treatment, according to Praxis Medical Insights 1

Oral Therapy Options

• Itraconazole 100 mg daily for 15 days has an 87% mycological cure rate, as recommended by the Pediatrics guideline 2
• Terbinafine 250 mg daily for 1-2 weeks is particularly effective against T. tonsurans, according to the Pediatrics guideline 2

Treatment Selection Based on Causative Organism

• Terbinafine appears superior for Trichophyton tonsurans infections, as stated in the Pediatrics guideline 2
• Itraconazole has shown superior efficacy compared to griseofulvin, with an 87% vs 57% mycological cure rate, according to the Pediatrics guideline 2

Prevention and Special Considerations

• Prevention measures, such as avoiding skin-to-skin contact with infected individuals, not sharing towels and other personal items, covering lesions, and properly cleaning contaminated combs and brushes, are essential to avoid recurrence, as recommended by the Pediatrics guideline and Praxis Medical Insights 1 2

Treatment Monitoring and Follow-up

• Follow-up should include both clinical and mycological assessment, and treatment failure may require extending treatment duration, according to Praxis Medical Insights 1

Treatment of Tinea Corporis

Diagnostic Approach

• Accurate diagnosis is essential before initiating treatment, ideally confirmed through microscopy using potassium hydroxide preparation or culture to identify the causative organism, and specimens should be collected using scalpel scraping, hair pluck, brush, or swab as appropriate to the lesion, according to the British Journal of Dermatology 3

Prevention and Management of Recurrence

• Implement preventive measures, including cleaning contaminated combs and brushes with disinfectant, and screen and treat family members if infection is caused by anthropophilic species, as recommended by the British Journal of Dermatology 4

Monitoring and Follow-up

• The definitive endpoint for treatment should be mycological cure, not just clinical response, and follow-up with repeat mycology sampling is recommended until mycological clearance is documented, according to the British Journal of Dermatology 5

Oral Antifungal Treatment for Recurrent Tinea Corporis

Primary Treatment Considerations

• Itraconazole is licensed for children over 12 years in the UK, though used off-label in younger children in some countries, and has important drug interactions to consider, including enhanced toxicity with warfarin, certain antihistamines, antipsychotics, midazolam, digoxin, and simvastatin, according to the British Journal of Dermatology 6
• The British guideline society recommends that fluconazole can be considered as a third-line option, but has significant limitations, including not being licensed for tinea in children under 10 years in the UK, and being less cost-effective than terbinafine with limited comparative efficacy data 6

Management of Recurrent Infections

• The British guideline society suggests that screening and treating all family members, especially with anthropophilic species like Trichophyton tonsurans, is crucial, as over 50% of family members may be affected 6
• Cleaning all fomites, such as hairbrushes, combs, and towels, with disinfectant or 2% sodium hypochlorite solution is recommended to prevent the spread of infection, according to the British Journal of Dermatology 6

Treatment Approach

• The British guideline society recommends against using griseofulvin as first-line treatment, as it requires longer treatment duration, is less effective than terbinafine, and has lower cure rates 7

Treatment of Tinea Corporis with Topical Antifungals

Topical Treatment Regimens

• The British Journal of Dermatology recommends clotrimazole cream applied twice daily for 2-4 weeks for mild to moderate tinea corporis 8
• The British Journal of Dermatology suggests miconazole cream applied twice daily for 2-4 weeks for mild to moderate tinea corporis 8
• Baseline liver function tests are recommended before initiating terbinafine or itraconazole, especially with pre-existing hepatic abnormalities, according to the British Journal of Dermatology 8

Evidence‑Based Management of Tinea Corporis in Children

Topical Antifungal Agents

• Terbinafine 1 % cream is available over‑the‑counter and provides a highly effective, short‑duration topical treatment for uncomplicated tinea corporis in otherwise healthy adolescents. 9
• In randomized studies, clotrimazole 1 % cream applied twice daily achieved a mycological cure rate approximately 2.9‑fold higher than placebo in adolescents with tinea corporis. 9

Indications for Switching to Oral Therapy

• Failure of appropriate topical therapy after 2–4 weeks is an indication to consider systemic antifungal treatment in pediatric patients with extensive or refractory tinea corporis. 10

Oral Antifungal Options and Licensing

• Itraconazole 100 mg once daily for 15 days is approved for use in children older than 12 years in the United Kingdom for the treatment of tinea corporis. 11
• Fluconazole 150 mg once weekly for 2–3 weeks can be used as an alternative systemic agent for tinea corporis, although it is less commonly prescribed and is not licensed for children under 10 years of age in the United Kingdom. 12

Drug Interactions and Safety of Oral Agents

• Oral terbinafine 250 mg daily for 1–2 weeks is generally well tolerated in adolescents, with gastrointestinal upset or rash occurring in fewer than 8 % of patients. 9
• Itraconazole has important drug‑interaction risks: toxicity is increased when combined with warfarin, certain antihistamines (e.g., terfenadine, astemizole), midazolam, digoxin, and simvastatin; efficacy may be reduced by H₂‑blockers, phenytoin, and rifampicin. 10

Public‑Health Considerations

• School attendance does not need to be restricted for children receiving appropriate antifungal therapy for tinea corporis; exclusion is unnecessary once treatment has been initiated. 10